Why levofloxacin is the order to question
Fluoroquinolones such as levofloxacin have a boxed warning for worsening
myasthenia gravis and can precipitate
myasthenic crisis. The mechanism is a direct inhibition of acetylcholine release at the neuromuscular junction, which reduces the already limited postsynaptic signaling in MG. In a retrospective single-center study, fluoroquinolone use was associated with MG exacerbation, and the exacerbations occurred as early as
15 minutes to
4 days after exposure
[1][4]. Postmarketing surveillance data from the US FDA Adverse Event Reporting System also support a signal linking fluoroquinolones to acute MG worsening
[2].
Because this patient already has fever and a productive cough, an infection is likely driving her current weakness, but adding levofloxacin could paradoxically worsen neuromuscular transmission and push her toward respiratory failure. The nurse should therefore clarify the order before administration and request a safer alternative.
Why the other orders are acceptable
| Order | Rationale for safety in MG |
|---|
| Ceftriaxone 1 g IV once daily | Third-generation cephalosporin; no clinically significant neuromuscular blockade. Appropriate empiric coverage for community-acquired pneumonia while sputum culture is pending [3]. |
| Paracetamol 500 mg PO q6h PRN | Antipyretic with no effect on neuromuscular transmission; safe for fever management. |
| Omeprazole 20 mg PO once daily | Proton pump inhibitor used for gastric protection during prednisone therapy; no meaningful MG interaction. |
Clinical reasoning for the nurse
The patient is on
pyridostigmine, a cholinesterase inhibitor, and
prednisone, an immunosuppressant. Infection itself is a well-known trigger of MG exacerbation, so treating the pneumonia is essential. However, the choice of antibiotic matters.
Fluoroquinolones, aminoglycosides, and intravenous magnesium are the classic drug classes to avoid or question in MG because they impair neuromuscular transmission. A macrolide such as azithromycin may also warrant caution, although the association is less consistently reported than with fluoroquinolones
[1][2].
Watch out! A boxed warning means the risk is serious enough that the FDA requires prominent labeling. It does not mean the drug is absolutely contraindicated in every MG patient, but it does mean the prescriber must be alerted so the risk-benefit decision is explicit.
Key point! The nurse’s role is not to independently stop the order, but to
clarify with the physician before giving levofloxacin, because a safer antibiotic such as ceftriaxone is already ordered and available for this pneumonia.
References (research sources)
- [1]
Frequency and Severity of Myasthenia Gravis Exacerbations Associated With the Use of Ciprofloxacin, Levofloxacin, and Azithromycin.Research articleUysal SP, Li Y, Thompson NR, Li Y. (2025) · DOI: 10.1002/mus.28410
- [2]
Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.Research articleJones SC, Sorbello A, Boucher RM (2011) · DOI: 10.2165/11593110-000000000-00000
- [3]
Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.Research articleChen X, Ding J, Zhang J, Dai H, Yu L. (2025) · DOI: 10.3389/fphar.2025.1695526
- [4]
[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].Research articleWang SH, Xie YC, Jiang B, Zhang JY, Qu Y, Zhao Y (2013)